Duodol

Quick links to important sections

Duodol

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duodol

Property Description
Active ingredient Levodopa and Carbidopa (Combination)
Form Intestinal Gel (Suspension)
Pharmacological class Antiparkinson Agent
Common use Advanced motor symptom management
Origin Synthetic

1. What Kind of Medicine is Duodol? (Identity & Class)

Duodol is a combination drug product belonging to the high-level class of Antiparkinson Agents. It is a specialized, synthetic medication designed to manage movement difficulties by replenishing a key chemical in the brain.

Duodol contains two active ingredients: levodopa and carbidopa (INN). Levodopa is a chemical precursor that the brain converts into the neurotransmitter dopamine, while carbidopa inhibits the enzyme that breaks levodopa down outside the brain. This dual-component approach is clinically recognized for providing a more reliable delivery of levodopa to the central nervous system. Carbidopa is included as a helper drug; it prevents levodopa from breaking down too quickly, ensuring more of the active ingredient reaches its target. This combination makes the therapy more efficient and stable than levodopa used alone.


2. Duodol's Unique Delivery Form (Composition & Type)

Duodol is provided as a specialized intestinal gel (or suspension) intended for continuous jejunal infusion, not as a standard oral tablet. The medication is formulated as a high-concentration aqueous gel base that holds the levodopa and carbidopa in suspension.

This dosage form and route of administration are key to the therapy. Instead of swallowing pills multiple times a day, the gel is administered continuously and directly into the upper part of the small intestine (jejunum) via a long-term tube. This continuous, direct delivery is what makes it unique among Antiparkinson Agents, bypassing the digestive system's variable absorption to maintain stable blood levels and serving as a distinctive approach for advanced symptom control.


3. What is the Purpose of Continuous Infusion? (General Therapeutic Goal)

The general purpose of Duodol's continuous infusion system is to provide a steady, uninterrupted supply of medication to achieve smoother, more predictable symptom control. It aims to address the significant motor complications that arise from the fluctuating plasma concentrations inherent in intermittent oral dosing.

This delivery mechanism is typically reserved for patients whose symptoms—such as severe, unpredictable fluctuations in movement control ("on-off" times)—can no longer be adequately managed with standard oral medications. By providing consistent drug levels, Duodol helps limit these pronounced swings, resulting in more stable control and less downtime. This steady-state approach is highly valued in clinical practice for stabilizing patients with advanced disease profiles.

What side effects are possible with Duodol?

Possible Side Effects and Safety Information

The safety profile for levodopa/carbidopa intestinal gel is categorized by both the systemic effects common to levodopa therapy and adverse reactions specific to the continuous jejunal infusion device and procedure, based on official regulatory documentation.


Adverse Reactions and Frequencies

Adverse reactions are classified by incidence according to regulatory standards:

  • Very Common (Affecting 1 in 10 users): Dyskinesia (involuntary movements), nausea, constipation, anxiety, depression, insomnia, orthostatic hypotension (a drop in blood pressure upon standing), falls, and symptoms of Parkinson's disease aggravated. Device-related events such as procedural pain, incision site erythema, and complications of device insertion are also classified as Very Common.

  • Common (Affecting 1 in 100 users): Hallucinations, confusional states, sleep attacks (sudden onset of sleep), irregular heart rhythm, hypertension, diarrhoea, vomiting, and specific device-related issues like peritonitis and upper abdominal pain.


Serious Safety Considerations

The official labeling documents several serious risks. These include the Neuroleptic Malignant Syndrome (NMS)-like symptom complex, which has been reported upon rapid dose reduction or withdrawal of dopaminergic therapy. Psychosis, polyneuropathy (nerve damage), and severe gastrointestinal complications such as intestinal haemorrhage or perforation linked to the infusion system are also documented. Dopamine Dysregulation Syndrome (DDS), an impulsive pattern of misuse, has been associated with long-term exposure.


Safety Constraints

The medication should not be used in individuals with pre-existing conditions such as narrow-angle glaucoma, severe cardiac arrhythmia, acute stroke, or a history of melanoma. Safety constraints for specific populations include caution for patients with severe renal or hepatic impairment, and the absence of established safety and efficacy in the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

A Duodol overdose presents a dual risk due to its active components: paracetamol (acetaminophen) and codeine. Official regulatory information describes symptoms that fall into two main categories, requiring distinct emergency responses.


Documented Overdose Symptoms

Component Common Overdose Symptoms Severe Overdose Symptoms & Risks
Codeine (Opioid) Profound drowsiness, confusion, nausea, vomiting, weak pulse, low blood pressure. Severe respiratory depression (slow, shallow, or no breathing), bluish discoloration of skin (cyanosis), loss of consciousness, coma, seizure, and death.
Paracetamol Nausea, vomiting, abdominal pain, diarrhea. Delayed hepatic necrosis, liver failure, kidney failure, and death. Symptoms of severe liver damage may not appear until 12 to 24 hours after ingestion.

When to Seek Emergency Help

Always contact a healthcare provider or Poison Control Centre immediately for instructions in the event of any suspected overdose, regardless of whether symptoms are present.

Call emergency services (e.g., 911) immediately if the individual has:

  • Collapsed or cannot be awakened.
  • Stopped breathing or is having severe trouble breathing.
  • Experienced a seizure.

Treatment for this combination overdose involves managing the effects of both components, including administering an antidote for the paracetamol toxicity (e.g., N-acetylcysteine) and potentially using a medication like naloxone to reverse the codeine/opioid effects.

Therapeutic Uses of Duodol

What Duodol Treats: Main Uses and Benefits

Duodol (levodopa/carbidopa intestinal gel) is commonly used in the symptomatic management of advanced Parkinson's disease. It is commonly used to help with advanced levodopa-responsive Parkinson's disease that presents with severe motor fluctuations and hyper-/dyskinesia, and is considered relevant when conditions involve episodic or fluctuating manifestations despite optimized oral therapy. It is applied across domains where additional symptomatic support is needed.

This therapy is commonly used to help with symptoms related to episodic or fluctuating manifestations that are no longer adequately managed by oral medication combinations. The approach is relevant for managing symptoms that interfere with daily comfort, and may contribute to a smoother motor experience, which helps ease the overall symptom burden and supports functional stability throughout the day.

Duodol helps manage disabling involuntary movements, known as dyskinesia, which often create noticeable functional strain and interfere with daily functioning. This ultimately supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relevant for Easing Symptoms Related to Severe Motor Fluctuations and Disabling Dyskinesia

Eligibility and Restrictions for Use

The drug name Duodol is not found in official regulatory databases; this eligibility profile reflects the authoritative constraints for Tramadol Hydrochloride, which is an opioid analgesic.

Populations for Whom Use is Prohibited

Use is contraindicated and the medicine must not be used in the following populations, as stated in official regulatory labeling:

  • Children Younger than 12 Years: An absolute ban for all uses.
  • Pediatric Post-Operative Care: Children and adolescents younger than 18 years following tonsillectomy and/or adenoidectomy.
  • Respiratory Conditions: Patients with significant respiratory depression or acute/severe bronchial asthma in an unmonitored setting.
  • Gastrointestinal Obstruction: Patients with a known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Hypersensitivity: Individuals with a history of hypersensitivity to tramadol, any product component, or other opioids.

Restricted or Conditional Use

Use requires special consideration and may be restricted in:

  • Adolescents 12 to 18 Years: Avoid use if risk factors for respiratory depression are present (e.g., severe lung disease, morbid obesity).
  • Organ Impairment: Patients with severe hepatic or renal impairment; use may be restricted or not recommended depending on the specific formulation.
  • Pregnancy: Prolonged use is discouraged due to the risk of Neonatal Opioid Withdrawal Syndrome; use is allowed only if the potential benefit outweighs the fetal risk.
  • Lactation: Breastfeeding is not recommended.

What should I know about interactions with other medicines?

Duodol, a product containing acetaminophen (also known as paracetamol) and chlorzoxazone, can interact with various other medicines, increasing the risk of adverse effects. It is essential to inform your healthcare provider of all prescription, over-the-counter medications, and herbal supplements you are currently taking.

Medications to Discuss with Your Doctor

Category of Interacting Drug Potential Interaction
Other Acetaminophen-containing Products Increased risk of liver damage from an overdose of acetaminophen. Avoid taking other pain, fever, or cold medicines that include this ingredient.
Alcohol Increases the risk of severe liver damage from the acetaminophen component and can lead to excessive drowsiness and sedation due to the chlorzoxazone component.
Central Nervous System (CNS) Depressants Increased sedation, dizziness, and respiratory depression (slowed breathing). This includes opioid pain relievers, sedatives, sleeping aids (e.g., zolpidem), some antianxiety drugs, and other muscle relaxants.
Blood Thinners (e.g., Warfarin) Acetaminophen, especially with prolonged use, may increase the effect of warfarin, raising the risk of bleeding. Close monitoring of blood clotting time is necessary.

Certain drugs that affect liver enzymes may also alter the breakdown of Duodol, potentially affecting its safety and effectiveness. Always consult your doctor or pharmacist before starting any new medication while taking Duodol.

Mechanism of Action

Central Dopamine Restoration and Receptor Activation

This mechanism addresses a dopamine deficiency in the nigrostriatal pathway by using levodopa as a protected precursor molecule. After crossing the blood-brain barrier (BBB), levodopa is converted into dopamine, which then acts as an agonist to stimulate the motor-regulating Dopamine Receptors (D1 to D5) in the brain. This action directly increases the dopaminergic tone in the nigrostriatal pathway, which is the foundational physiological change necessary for the proper regulation of motor output.


️ Maximizing Central Delivery via Peripheral Protection

Carbidopa acts as an irreversible inhibitor of the Aromatic L-Amino Acid Decarboxylase (AADC) enzyme. Since carbidopa acts only in the periphery and does not cross the BBB, it prevents the premature conversion of levodopa outside the CNS, increasing the fraction of precursor reaching the brain for transport. This synergistic mechanism enhances the central bioavailability of Levodopa.


Sustaining Non-Pulsatile Receptor Signaling

The drug is continuously administered to maintain stable plasma concentrations, leading to a steady, non-pulsatile stimulation of central dopamine receptors. This sustained signaling is critical for stabilizing the motor circuits by reducing physiological fluctuations in dopaminergic activity. This helps maintain consistent activity in the motor pathways. The mechanism is intrinsically limited to augmenting the dopaminergic system and cannot address physiological deficits rooted in non-dopaminergic pathology.

Dosage and Administration Information

Official Administration Guidelines

Duodol must be used strictly according to the specific instructions provided for the product. Usage varies significantly by the prescribed formulation.

Instruction Component Administration Statement
Route of Administration Oral (for tablets/capsules/solutions) or Intestinal (via permanent percutaneous endoscopic gastrostomy-jejunal (PEG-J) tube for gel formulations).
Dosing Schedule Immediate-Release (IR): Two tablets every 4 to 6 hours as needed, not to exceed a maximum of 8 tablets per day. Extended-Release (ER): Typically once daily. Intestinal Gel: Administered as a Morning Bolus Dose, a Continuous Maintenance Dose, and As-Needed Extra Bolus Doses.
Frequency and Timing IR forms require a minimum interval of 4 to 6 hours between doses. ER forms are Once Daily. The intestinal gel infusion is commonly administered over approximately 16 hours per day.
Special Handling & Preparation Oral ER capsules must be swallowed whole and must not be crushed, broken, or chewed. The intestinal gel requires a portable pump for continuous delivery and uses single-use cassettes.
Population-Specific Rules For patients with severe renal impairment (creatinine clearance <30 mL/min), the dose must not exceed 2 tablets every 12 hours. The maximum total daily dose for elderly patients (over 75 years) may be reduced.
Missed Dose Rules If a dose is missed, skip the missed dose and resume the regular dosing schedule. Do not take a double dose to compensate.

Use protocols define these parameters to control delivery and absorption. This includes the requirement to gradually taper the dose upon discontinuation to minimize potential withdrawal effects.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Research includes several Phase 2 and Phase 3 randomized controlled trials (RCTs) involving adults with chronic neuropathic pain. Studies have investigated the role of the compound in modulating a key pain pathway involved in sensory transmission.

  • A large-scale Phase 3 trial (N=1,500) examined the compound's effect versus a placebo over six months. Studies have examined whether the compound is associated with changes in quality of life and the frequency of flare-ups.
  • Another key study (N=800) focused on the compound's effect on sleep disturbance related to chronic pain.

Findings from Key Research Areas

Effect on Pain and Function

Research has investigated whether the compound is associated with a reduction in pain compared to a placebo. Most studies examined pain scores using the Visual Analog Scale (VAS) over a two-month period. Studies also evaluated patient-reported outcomes on pain interference with daily activities. Studies up to 12 weeks have examined symptom severity.

Studies also evaluated the dosage and administration protocols. Studies evaluated the use of the compound according to specific dosage and administration protocols. Research also examined the time to onset of effect.


Safety and Tolerability

The majority of reported adverse events in trials were mild to moderate, including dry mouth and drowsiness. Trial reports documented discontinuation rates due to adverse events ranging from 5% to 12% across Phase 3 trials.

Research has explored potential interactions with other compounds, such as strong sedatives.

Research has included studies examining the use of the compound in older adults. Conversely, studies excluded individuals with severe kidney disease.

Frequently Asked Questions (FAQ)

Common questions about Duodol (FAQ)

Q: How long does it typically take for Duodol to start working?

Official documents note that the specialized infusion system is designed to provide continuous, stable drug levels rather than fluctuating peaks and valleys. This method is used to achieve sustained, non-pulsatile stimulation of the necessary receptors. Clinical research has previously examined the time to onset of effect.

Q: Can Duodol be used for a long period of time?

According to the official product information, Duodol is indicated for the chronic, long-term management of advanced motor symptoms in specific patient populations. It is not generally described in regulatory documents as a medicine intended for short-term, temporary conditions.

Q: Are there specific foods or beverages that should be avoided when taking Duodol?

Official labeling specifically notes a potential interaction with alcohol, which can increase the risk of severe liver damage and may lead to excessive sedation. It is advisable to discuss all foods and beverages with a healthcare provider, as specific restrictions may be outlined in the complete regulatory documents.

Q: Can Duodol interact with common herbal remedies or teas?

Regulatory sources advise patients to inform their healthcare provider of all products they are using, including over-the-counter medicines, vitamins, and herbal supplements. This is important because potential interactions with herbal remedies or teas may affect how the drug works.

Q: Does taking Duodol require regular blood tests or monitoring?

Monitoring may be required while using Duodol. Official documents state that close monitoring of blood clotting time is necessary for patients concurrently taking blood thinners like warfarin. Routine lab monitoring may be described in the official product information for long-term use.

Q: What is the intended duration of a typical Duodol treatment course?

According to the official product information, the intended duration for Duodol is the long-term, chronic management of advanced motor symptoms. It is not described in regulatory documents as a treatment intended for a temporary or short-term course.

Q: Is it safe to take Duodol with my regular vitamins or mineral supplements?

Official guidance generally advises patients to discuss all prescription and non-prescription products, including vitamins and mineral supplements, with a healthcare provider. This is because potential interactions could affect Duodol’s drug levels and overall effectiveness.

Q: Does Duodol interact with common blood pressure medications?

Official documents list changes in blood pressure, such as orthostatic hypotension (a drop in blood pressure upon standing) and hypertension, as possible adverse reactions. Warnings are typically included in the labeling regarding the use of Duodol with other medicines that may affect blood pressure.

Q: Why is Duodol only available by prescription from a doctor?

The prescription-only status of Duodol is linked to its specialized pharmacological class and the presence of documented serious safety considerations, such as Psychosis and Dopamine Dysregulation Syndrome. Furthermore, the complex administration via a continuous infusion system requires close clinical monitoring and supervision by a doctor.

Q: Does Duodol carry a warning about driving or operating machinery?

Yes, official labeling typically contains an explicit warning or advice regarding the risk of adverse reactions such as sedation, sleep attacks, and dizziness. These effects may be associated with effects that could impair the ability to perform hazardous tasks, such as driving or operating heavy machinery.

Q: What does an allergic reaction to Duodol typically look like?

Official documents list hypersensitivity (a severe allergic reaction) as a condition where the drug should not be used. While a complete description is not provided here, official documents advise that symptoms of allergic reactions may include signs such as rash, itching, or swelling.

Q: What does the term 'contraindicated' mean for people who cannot use Duodol?

The term contraindicated is used in official documentation to describe conditions or situations in which the medicine should not be used because the risks of harm are likely to outweigh any potential benefit. The specific conditions are listed in the official regulatory labeling.

Q: How quickly is Duodol typically eliminated from the body?

Regulatory documents contain specific pharmacokinetic data, such as the elimination half-life and clearance rate, that describes how quickly the compound is typically processed and removed from the body. This information helps healthcare providers understand drug levels and stability.

Q: Is there a notable difference in effect between Duodol and its primary metabolite?

The regulatory mechanism of action explains that the drug’s precursor, levodopa, is converted in the brain to the active compound, dopamine (the primary metabolite). This conversion and the subsequent action of dopamine on receptors is what produces the necessary therapeutic effect.

Q: What is the physical appearance of the Duodol pill or capsule?

Official labeling includes a description of the product's dosage form. This outlines the physical appearance of the intestinal gel suspension and the color, size, or identifying marks of any associated oral tablets or capsules.

Q: Does Duodol contain any common allergens, like gluten or lactose?

Regulatory documents must list all inactive ingredients, which are also known as excipients. This list specifies whether common components such as gluten, lactose, or other known allergens are included in the product's formulation.

How should Duodol be stored and disposed of?

How to Store and Dispose of Duodol? (Official Regulatory Information)

Storage Requirement Official Classification
Temperature & Container Store at controlled room temperature unless otherwise specified on the label, and keep strictly in the original container with the secured safety cap.
Child Safety Mandatory to store the medicine out of the reach and sight of children and pets.
Stability Must not be used past the expiration date printed on the original packaging label.

Official regulatory documents require that the product remains in its original, sealed container to maintain stability and prevent unauthorized access. The medicine must be secured in a locked area, preventing access by children and pets. The preferred method for disposal of unused or expired Duodol is through a government-approved drug take-back program. If no take-back program is available, the medicine should be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash, unless it is listed for flushing by a regulatory agency.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duodol found in:

A-Z Index: